The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta

التفاصيل البيبلوغرافية
العنوان: The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta
المؤلفون: Bertram F. Pontz, Petra Wolf, Falk Mittag, Ingmar Ipach, Torsten Kluba
المصدر: Orthopedic Reviews
Orthopedic Reviews, Vol 4, Iss 3, Pp e29-e29 (2012)
بيانات النشر: Open Medical Publishing, 2012.
سنة النشر: 2012
مصطلحات موضوعية: bisphosphonate, ibandronate, Deoxypyridinoline, medicine.medical_specialty, Bone density, medicine.medical_treatment, Urology, osteogenesis imperfecta, Article, Bone remodeling, chemistry.chemical_compound, bone turnover markers, Internal medicine, medicine, Orthopedics and Sports Medicine, Orthopedic surgery, Creatinine, Pyridinoline, business.industry, bone density, Bisphosphonate, osteogenesis imperfecta, bisphospho- nate, ibandronate, bone density, bone turnover markers, medicine.disease, Endocrinology, chemistry, Osteogenesis imperfecta, Alkaline phosphatase, business, RD701-811
الوصف: Osteogenesis imperfecta (OI) is characterized by different signs including increased bone fragility, short stature, blue sclera, abnormal tooth growth and often secondary immobility. No curative therapy has been found for this rare disease up to now, and different pharmacological substances have been tried as treatment for severe forms of OI. Promising results were seen with intravenous bisphosphonates in the treatment of patients with OI. The aim of present study was to show the effect of intravenous ibandronate therapy on bone density and bone metabolism markers. We analyzed the data of 27 patients with the diagnosis of OI who were treated off-label with intravenous ibandronate. Ibandronate was administered by intravenous infusion every three months at a dosage of 0.3-2 mg. Bone turnover markers and bone density were measured before starting therapy and every three months during treatment. Bone density was measured by using an ultrasound imaging system providing an accurate image of the calcaneus and by evaluating broadband ultrasound attenuation (BUA). Twenty-seven patients were treated with intravenous iban- dronate during the observation period. 18 were female. The mean age of all patients was 23.9 years ± 19.6 (range 4-63). Seventeen patients were categorized to have OI Type I, 5 patients to have OI Type III and 5 patients to have OI Type IV. There was a statistically significant decrease in total alkaline phosphatase (P
تدمد: 2035-8164
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d7ccf0a51d50630713dcde1dd6ba053Test
https://doi.org/10.4081/or.2012.e29Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....3d7ccf0a51d50630713dcde1dd6ba053
قاعدة البيانات: OpenAIRE